AMERICAN ORIENTAL BIOENGINEERING RATED 'BUY/4'

American Oriental Bioengineering has been rated 'Buy/4' in an initiating Institutional report by Investrend Research analyst Kipley Lytel, CFA, and assigned a target valuation of $6. The full report is at http://www.investrendresearch.com. In it the analyst also stated: The rating is predicated on the price gap between AOB's current stock price and the implied company intrinsic value, along with:(1) AOB's 10+ year seasoned history recently marked by visible operational execution; (2) 81% revenue and 85% net income year-over-year comparable period increases for the nine-month period ended Sept. 30, 2005 (9mo2005), respectively.
Business Wire